(Q51581916)

7 April 2018

title

Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. (English)

1 reference

7 April 2018

1 reference

1 reference

K Skandalis

1

1 reference

7 April 2018

M Spirova

2

1 reference

7 April 2018

G Gaitanis

3

1 reference

7 April 2018

A Tsartsarakis

4

1 reference

7 April 2018

I D Bassukas

5

1 reference

7 April 2018

publication date

6 April 2011

1 reference

7 April 2018

Journal of the European Academy of Dermatology and Venereology

published in

1 reference

7 April 2018

volume

26

1 reference

7 April 2018

issue

2

1 reference

7 April 2018

page(s)

249-253

1 reference

7 April 2018

Incretin-based therapies for type 2 diabetes mellitus

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

Seprase: an overview of an important matrix serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

Sitagliptin-associated drug allergy: review of spontaneous adverse event reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

CD26/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04062.X

10.1111/J.1468-3083.2011.04062.X

21 January 2018

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

21466592

1 reference

7 April 2018